



Biobeat has developed an AI-based end-to-end solution for remote patient monitoring. The core of the technology lies in Biobeat's proprietary sensor, which is able to monitor 15 vital signs wirelessly, continuously and non-invasively.

Website: [www.bio-beat.com](http://www.bio-beat.com)

## COMPANY OVERVIEW

Model: **B2B**

Founded: **2016**

Location: **Israel**

Industries Verticals: **Medical device, Digital health, Remote patient monitoring**

Potential Market Size: **\$26B in 2020, \$38B by 2025**

Funds raised: **10M USD**

Company stage: **Revenue growth**

Commercial stage: **Achieved 6 regulatory approvals including FDA, CE and ARTGA.**

## PROPOSITION

Biobeat develops unique wearable devices for remote, continuous, wireless, accurate, medical-grade monitoring of 15 vital signs including continuous blood pressure (only company worldwide to hold FDA for continuous BP), oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat

The company is developing AI based algorithms to analyze the massive amount of data generated to develop new Biomarkers & Predictive Analytics

## TEAM



**Arik Ben Ishay CEO Founder**  
Former director of innovation in the Rocket and Space department of the Ministry of Defense.  
LL.B, CPA



**Johanan May CTO Founder**  
Former head of system development and integration division at Lodan Group.  
Aeronautical engineer



**Israel Sarussi VP R&D Founder**  
Former CEO of SPO Medical Inc.  
40+ years of experience in the PPG field.  
Pioneer of the reflective PPG technology.  
Electrical engineer

## HIGHLIGHTS

\$5M in sales across the US and Europe.

Implemented in 13 Hospitals in under 4 weeks for COVID-19 monitoring.

Multiple signed MSAs with the world's biggest pharma companies and CROs.

Several paid pilots and POCs lined up in the US throughout the next year.